Mikael Dolsten - 27 Feb 2026 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role
Director
Signature
/s/ David Watson, attorney-in-fact for Mikael Dolsten
Issuer symbol
APLS
Transactions as of
27 Feb 2026
Net transactions value
+$505,870
Form type
4
Filing time
03 Mar 2026, 16:06:32 UTC
Previous filing
03 Dec 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Dolsten Mikael Director C/O APELLIS PHARMACEUTICALS, INC., WALTHAM /s/ David Watson, attorney-in-fact for Mikael Dolsten 03 Mar 2026 0001437590

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Award $0 +14,312 $0.000000 14,312 27 Feb 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Award $505,870 +24,135 $20.96 24,135 27 Feb 2026 Common Stock 24,135 $20.96 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This restricted stock unit was granted on February 27, 2026. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election.
F2 This represents a stock option award granted February 27, 2026 that vest 1/3rd per year over a three-year period subject to continued service.